Immunovant (IMVT) Competitors $18.82 -0.08 (-0.42%) As of 03:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMVT vs. SLNO, VTRS, ROIV, BBIO, MRNA, QGEN, ELAN, VRNA, RVMD, and ABVXShould you be buying Immunovant stock or one of its competitors? The main competitors of Immunovant include Soleno Therapeutics (SLNO), Viatris (VTRS), Roivant Sciences (ROIV), BridgeBio Pharma (BBIO), Moderna (MRNA), QIAGEN (QGEN), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), and Abivax (ABVX). These companies are all part of the "medical" sector. Immunovant vs. Its Competitors Soleno Therapeutics Viatris Roivant Sciences BridgeBio Pharma Moderna QIAGEN Elanco Animal Health Verona Pharma PLC American Depositary Share Revolution Medicines Abivax Immunovant (NASDAQ:IMVT) and Soleno Therapeutics (NASDAQ:SLNO) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk. Do analysts recommend IMVT or SLNO? Immunovant presently has a consensus target price of $28.78, suggesting a potential upside of 52.91%. Soleno Therapeutics has a consensus target price of $115.92, suggesting a potential upside of 80.06%. Given Soleno Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Soleno Therapeutics is more favorable than Immunovant.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunovant 1 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.58Soleno Therapeutics 1 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.93 Do insiders & institutionals hold more shares of IMVT or SLNO? 47.1% of Immunovant shares are held by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are held by institutional investors. 1.8% of Immunovant shares are held by company insiders. Comparatively, 6.4% of Soleno Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is IMVT or SLNO more profitable? Soleno Therapeutics' return on equity of -73.74% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets ImmunovantN/A -80.99% -72.23% Soleno Therapeutics N/A -73.74%-56.67% Does the media prefer IMVT or SLNO? In the previous week, Soleno Therapeutics had 12 more articles in the media than Immunovant. MarketBeat recorded 13 mentions for Soleno Therapeutics and 1 mentions for Immunovant. Immunovant's average media sentiment score of 1.03 beat Soleno Therapeutics' score of 0.63 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Soleno Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, IMVT or SLNO? Immunovant has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -2.75, indicating that its stock price is 375% less volatile than the S&P 500. Which has stronger earnings and valuation, IMVT or SLNO? Soleno Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunovantN/AN/A-$413.84M-$2.85-6.60Soleno TherapeuticsN/AN/A-$175.85M-$4.14-15.55 SummarySoleno Therapeutics beats Immunovant on 9 of the 13 factors compared between the two stocks. Get Immunovant News Delivered to You Automatically Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMVT vs. The Competition Export to ExcelMetricImmunovantMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.28B$3.42B$6.18B$10.68BDividend YieldN/A2.24%5.72%4.86%P/E Ratio-6.6023.2229.6728.51Price / SalesN/A480.11579.48129.35Price / CashN/A45.5937.1261.42Price / Book4.5210.3312.086.53Net Income-$413.84M-$52.53M$3.32B$276.85M7 Day Performance8.10%-0.32%-0.31%0.19%1 Month Performance26.31%10.78%5.71%1.71%1 Year Performance-37.31%14.14%65.71%33.13% Immunovant Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMVTImmunovant2.2468 of 5 stars$18.82-0.4%$28.78+52.9%-36.1%$3.28BN/A-6.60120Positive NewsSLNOSoleno Therapeutics4.2803 of 5 stars$64.27+0.8%$115.92+80.4%+24.7%$3.39BN/A-15.5230VTRSViatris3.1288 of 5 stars$9.86+1.2%$10.40+5.5%-10.8%$11.36B$14.74B-3.4032,000Analyst ForecastROIVRoivant Sciences2.8749 of 5 stars$16.21+1.1%$19.94+23.0%+53.1%$10.95B$29.05M-23.16860BBIOBridgeBio Pharma4.5827 of 5 stars$55.96+0.8%$63.94+14.3%+113.5%$10.61B$221.90M-13.68400Analyst ForecastMRNAModerna4.2628 of 5 stars$26.74-0.3%$41.81+56.4%-49.7%$10.48B$3.24B-3.555,800Trending NewsAnalyst ForecastGap DownQGENQIAGEN4.1075 of 5 stars$47.30+1.0%$49.40+4.4%+18.4%$10.41B$1.98B27.955,765ELANElanco Animal Health2.7239 of 5 stars$20.04+1.4%$19.14-4.5%+70.9%$9.82B$4.44B23.309,000Analyst ForecastVRNAVerona Pharma PLC American Depositary Share1.077 of 5 stars$106.91flat$109.00+2.0%N/A$9.21B$42.28M-107.9930Positive NewsRVMDRevolution Medicines4.2957 of 5 stars$48.75+1.1%$74.64+53.1%+12.4%$9.02B$11.58M-10.83250News CoverageAnalyst UpgradeABVXAbivax3.4857 of 5 stars$95.63+2.0%$114.25+19.5%+763.9%$7.30BN/A0.0061Short Interest ↓ Related Companies and Tools Related Companies SLNO Competitors VTRS Competitors ROIV Competitors BBIO Competitors MRNA Competitors QGEN Competitors ELAN Competitors VRNA Competitors RVMD Competitors ABVX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMVT) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
